Black phosphorus nanosheet-promoted prodrug activation for enhanced cancer therapy

  • Mater Today Bio. 2026 May 17:38:103244. doi: 10.1016/j.mtbio.2026.103244.
Nan Yang  1  2 Dabao Zha  3 Changyu Cao  2 Ruigang Liu  2 Hanjun Sun  2 Xuejiao Song  2 Yanling Li  3 Xiaoji Xie  2 Xiaochen Dong  2  3 Yu Cai  1
Affiliations
  • 1. Center for Rehabilitation Medicine, Rehabilitation & Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, 310014, China.
  • 2. State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM), School of Flexible Electronics (Future Technologies), Nanjing Tech University (NanjingTech), Nanjing, 211816, China.
  • 3. School of Chemistry & Materials Science, School of Physics and Electronic Engineering, Jiangsu Normal University, Xuzhou, 221116, China.
Abstract

Tumor hypoxia-activated prodrugs possess great potential for Cancer therapy. However, their therapeutic effects are still limited by several factors, including suboptimal conversion to the active pharmaceutical ingredient in complex tumor environments. Here, we demonstrate a strategy using black phosphorus nanosheets (BPNSs) to boost the activation and therapeutic effects of a tumor hypoxia-activated prodrug, banoxantrone dihydrochloride (AQ4N). BPNSs can facilitate the activation of AQ4N to a toxic Anticancer drug through their degradation, which consumes oxygen and acidifies the surrounding environment, and their selective interaction with AQ4N under slightly acidic conditions, which can activate AQ4N. Moreover, the combination of BPNSs and AQ4N can result in synergistic Anticancer effects as an additional benefit. Using the features of BPNSs, an enhanced Cancer therapy without obvious toxic side effects was achieved using AQ4N in a mouse model.

Keywords
Black phosphorus; Cancer therapy; Hypoxia; Prodrug; Tumor.
Products